Eiffel to collaborate with Singapore company
Tuesday, 29 June, 2004
Eiffel Technologies (ASX: EIF) has signed an agreement with Singapore company NanoMaterials Technology to jointly develop new technology for drug reengineering.
The aim of the collaboration is to develop a hybrid technology that combines Eiffel's supercritical fluids, which provides performance benefits, with NanoMaterials' high gravity controlled precipitation technology, which brings with it advantages in production efficiency, opening up potential commercial opportunities for reengineering drugs where cost is an issue.
Feasibility studies are underway in Singapore to test the hybrid concept on anti-inflammatory and asthma drugs with results expected in August. If successful the companies expect to work together on drug targets that are underperforming or under threat from generic competition.
"Successfully combining these complementary nanotechnologies would enable us to aggressively pursue the re-engineering of cost sensitive drugs, through our own development work or in collaboration with the owners of the drugs under competitive threat," said Eiffel CEO Christine Cussen.
The two companies will jointly own new technology developed as a result of the collaboration.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
